Clinical Trials
72 trialsPANGEA
UNC Lineberger Comprehensive Cancer Center
A Study of XL184 (Cabozantinib) With or Without Erlotinib in Subjects With Non-Small Cell Lung Cancer (NSCLC)
Exelixis
Phase I/II of Oral Vorinostat Combination With Erlotinib in NSCLC Patients With EGFR Mutations With DP After Erlotinib.
Spanish Lung Cancer Group
Erlotinib Hydrochloride and Onalespib Lactate in Treating Patients With Recurrent or Metastatic EGFR-Mutant Non-small Cell Lung Cancer
National Cancer Institute (NCI)
A Study of BGB324 (Bemcentinib) in Combination With Erlotinib in Patients With Non-Small Cell Lung Cancer
BerGenBio ASA
Nintedanib Plus EGFR TKI In EGFR-mutated Non-small Cell Lung Cancer Patients
China Medical University Hospital
A Study of ASP2215 in Combination With Erlotinib in Subjects With Epidermal Growth Factor Receptor (EGFR) Activating Mutation-Positive (EGFRm+) Advanced Non-Small-Cell Lung Cancer (NSCLC) Who Have Acquired Resistance to an EGFR Tyrosine Kinase Inhibitor (TKI)
Astellas Pharma Inc
A Phase 1/2 Trial of Trametinib and Erlotinib in Patients With EGFR-Mutant Lung Adenocarcinomas and Acquired Resistance to Erlotinib
Memorial Sloan Kettering Cancer Center
Erlotinib Hydrochloride in Preventing Liver Cancer in Patients With Cirrhosis of the Liver
National Cancer Institute (NCI)
MET/VEGFR2 Inhibitor GSK1363089 and Erlotinib Hydrochloride or Erlotinib Hydrochloride Alone in Locally Advanced or Metastatic NSCLC That Has Not Responded to Previous Chemotherapy
Canadian Cancer Trials Group
MK-3475-021
Merck Sharp & Dohme LLC
Study to Evaluate Erlotinib With or Without SNDX-275 (Entinostat) in the Treatment of Patients With Advanced NSCLC
Syndax Pharmaceuticals
TUSC2-nanoparticles and Erlotinib in Stage IV Lung Cancer
Genprex, Inc.
S0727 Gemcitabine Hydrochloride and Erlotinib Hydrochloride With or Without Monoclonal Antibody Therapy in Treating Patients With Metastatic Pancreatic Cancer That Cannot Be Removed By Surgery
National Cancer Institute (NCI)
A Study of LY3499446 in Participants With Advanced Solid Tumors With KRAS G12C Mutation
Eli Lilly and Company
Phase I / II Vorinostat, Erlotinib and Temozolomide for Recurrent Glioblastoma Multiforme (GBM)
M.D. Anderson Cancer Center
Study of Erlotinib With or Without Investigational Drug (U3-1287) in Subjects With Advanced Non-small Cell Lung Cancer
Daiichi Sankyo
A Study of Enzastaurin and Erlotinib in Participants With Solid Tumors and Lung Cancer
Eli Lilly and Company
CheckMate370
Bristol-Myers Squibb
A Trial of Belinostat in Combination With Erlotinib in Patients With Non-small Cell Lung Cancer
Herlev Hospital
Trastuzumab and Erlotinib as First-Line Therapy in Treating Women With Metastatic Breast Cancer Associated With HER2/Neu Overexpression
Jonsson Comprehensive Cancer Center
MK-0646 and Gemcitabine +/- Erlotinib for Patients With Advanced Pancreatic Cancer
M.D. Anderson Cancer Center
Erlotinib, Paclitaxel, and Carboplatin Combined With Radiation Therapy for Stage III Non-Small Cell Lung Cancer
Case Comprehensive Cancer Center
Hsp90 Inhibitor AUY922 and Erlotinib Hydrochloride in Treating Patients With Stage IIIB-IV Non-Small Cell Lung Cancer
Northwestern University
Study of CG200745 PPA in Combination With Gemcitabine and Erlotinib for Advanced Pancreatic Cancer
CrystalGenomics, Inc.
Study of Bevacizumab and Erlotinib for Patients With Hormone Refractory Prostate Cancer
Columbia University
Trial of Ruxolitinib and Erlotinib in Patients With EGFR-mutant Lung Adenocarcinoma With Acquired Resistance to Erlotinib
Memorial Sloan Kettering Cancer Center
Intensity-Modulated Radiation Therapy, Pemetrexed, and Erlotinib in Treating Patients With Recurrent or Second Primary Head and Neck Cancer
Wake Forest University Health Sciences
Docetaxel and Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer or Other Solid Tumors
University of California, Davis
Avastin and Tarceva for Locally Advanced or Metastatic Non-Squamous Non-Small-Cell Lung Cancer
M.D. Anderson Cancer Center
A Study of Alectinib (RO5424802) in Participants With Non-Small Cell Lung Cancer Who Have Anaplastic Lymphoma Kinase (ALK) Mutation and Failed Crizotinib Treatment
Hoffmann-La Roche
Erlotinib and Cisplatin in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
University Health Network, Toronto
Bevacizumab and Erlotinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
National Cancer Institute (NCI)
Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Participants With Advanced Solid Tumors (P04722, MK-7454-004)
Merck Sharp & Dohme LLC
Sorafenib Combined With Erlotinib, Tipifarnib, or Temsirolimus in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma
National Cancer Institute (NCI)
Study to Assess Safety and Tolerability of MLN8237, In Combination With Erlotinib to Treat Non-Small Cell Lung Cancer
Fox Chase Cancer Center
Bendamustine and Erlotinib in Treating Patients With Stage IIIB, Stage IIIC, or Stage IV Breast Cancer
Ohio State University Comprehensive Cancer Center
Erlotinib in Treating Patients With Recurrent Malignant Glioma or Recurrent or Progressive Meningioma
National Cancer Institute (NCI)
AMG 102 and Erlotinib for Advanced Non-Small Cell Lung Cancer
University of Pittsburgh
Combination Chemotherapy, Bev, RT, and Erlotinib in Treating Patients With Stage III Non-Small Cell Lung Cancer
UNC Lineberger Comprehensive Cancer Center
Bevacizumab, Erlotinib and 5-Fluorouracil With External Beam Radiation Therapy in Locally Advanced Rectal Cancer
Massachusetts General Hospital
Erlotinib and Cetuximab in Treating Patients With Advanced Solid Tumors With Emphasis on Non-Small Cell Lung Cancer
University of California, Davis
Erlotinib, Celecoxib and Reirradiation for Recurrent Head and Neck Cancer
Icahn School of Medicine at Mount Sinai
A Study of Changes in FDG- and FLT-PET Imaging in Patients With Non-Small Cell Lung Cancer Following Treatment With Erlotinib
Genentech, Inc.
Phase I/II Trial of Bevacizumab, Pemetrexed and Erlotinib in Elderly Patients With Non-Small Cell Lung Cancer
H. Lee Moffitt Cancer Center and Research Institute
TARGET
Royal Marsden NHS Foundation Trust
First Line Bio-immunotherapy With Thymosin Alpha 1 in Patients With Sensitizing EGFR Mutation Positive Non Small Cell Lung Cancer Who Are Taking Standard of Care Therapy
SciClone Pharmaceuticals
A Study of MM-121 Combination Therapy in Patients With Advanced Non-Small Cell Lung Cancer
Merrimack Pharmaceuticals
Dasatinib and Erlotinib in Non-Small Cell Lung Cancer (NSCLC)
M.D. Anderson Cancer Center
Study of Pegylated Alfa Interferon, Sunitinib and Tarceva in Patients With Metastatic RCC
The Methodist Hospital Research Institute